SCHEMBL16202030

SCHEMBL16202030

CCO/N=C(\C)c1cc(C)c(C)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.36
RXRG P48443 2/20 0.36
RXRB P28702 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
ADRA1A P35348 1/20 0.35
LMNA P02545 3/20 0.34
PTBP1 P26599 1/20 0.34
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.30
HSD17B10 Q99714 1/20 0.30
KMT2A Q03164 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14099905 0.84 TSHR (0.38) RXRARXRGRXRBLMNAHTT
SCHEMBL14099978 0.84 SMN1; SMN2 (0.40) RXRARXRGRXRBSMN1; SMN2ADRA1A
SCHEMBL16202015 0.82 SMN1; SMN2 (0.41) RXRARXRGRXRBSMN1; SMN2LMNA
SCHEMBL14099948 0.80 MEN1 (0.40) SMN1; SMN2ADRA1AALDH1A1HPGDHSD17B10
SCHEMBL14430187 0.79 ADRA1A (0.45) SMN1; SMN2ADRA1ALMNAMAPK1HTT
SCHEMBL16202064 0.79 LMNA (0.31) SMN1; SMN2LMNAPTBP1PPARGPPARA
SCHEMBL16202057 0.78 PPARG (0.51) RXRARXRGRXRBSMN1; SMN2LMNA
SCHEMBL16202023 0.78 GSK3B (0.32) RXRARXRGRXRBADRA1A
SCHEMBL16202017 0.78 MAPT (0.33) SMN1; SMN2LMNAPTBP1ALDH1A1HPGD
SCHEMBL16202079 0.77 RXRA (0.34) RXRARXRGRXRBSMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2016-09-01 US disclosed
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-26 US disclosed
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi BASF SE (DE) 2016-05-26 US disclosed
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-05 US disclosed
US-9271501-B2 Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors BASF SE (DE) 2016-03-01 US disclosed
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI SNX1, DPM1, SNU13 RXRA 4465/4885RXRG 4376/4885RXRB 4450/4885
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI DPM1, CROCC, SNX1 RXRA 4379/4885RXRG 4122/4885RXRB 4400/4885
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi DPM1, CROCC, SNX1 RXRA 4379/4885RXRG 4122/4885RXRB 4400/4885
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB RXRA 4724/4885RXRG 4552/4885RXRB 4037/4885
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB RXRA 4724/4885RXRG 4552/4885RXRB 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.